{"id":742254,"date":"2012-02-07T08:30:00","date_gmt":"2012-02-07T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/"},"modified":"2023-03-22T00:04:26","modified_gmt":"2023-03-22T04:04:26","slug":"merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/","title":{"rendered":"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar"},"content":{"rendered":"<p class=\"bwalignc\">       Company Will Review Data FromTRA-2P and TRACER With External Experts        to Inform Next Steps     <\/p>\n<p>\n      Merck (NYSE:MRK), known outside the United States and Canada as MSD,<br \/>\n      today announced the top-line results of the TRA-2P (<b>T<\/b>hrombin <b>R<\/b>eceptor<br \/>\n      <b>A<\/b>ntagonist in <b>S<\/b>econdary <b>P<\/b>revention of<br \/>\n      atherothrombotic ischemic events) study of vorapaxar. Merck is<br \/>\n      developing vorapaxar, an investigational oral Protease Activated<br \/>\n      Receptor 1 (PAR-1) thrombin receptor antagonist, for the prevention of<br \/>\n      thrombosis, or clot formation, and the reduction of cardiovascular<br \/>\n      events.\n    <\/p>\n<p>\n      TRA-2P showed that the addition of vorapaxar to standard of care<br \/>\n      significantly reduced the risk of the protocol-specified primary<br \/>\n      endpoint of the composite of cardiovascular death (CVD), heart attack<br \/>\n      (myocardial infarction, or MI), stroke or urgent coronary<br \/>\n      revascularization compared to standard of care. There was a significant<br \/>\n      increase in bleeding, including intracranial hemorrhage (ICH), among<br \/>\n      patients taking vorapaxar in addition to standard of care, although<br \/>\n      there was a lower risk of ICH in patients without a history of stroke.\n    <\/p>\n<p>\n      The full results of TRA-2P will be presented at the American College of<br \/>\n      Cardiology Scientific Sessions in March.\n    <\/p>\n<p>\n      &#8220;In developing vorapaxar, Merck and our scientific collaborators set a<br \/>\n      very high bar \u2013 would the addition of vorapaxar to standard of care<br \/>\n      provide incremental benefit in preventing clots?&#8221; said Peter S. Kim,<br \/>\n      president, Merck Research Laboratories. &#8220;We are pleased that TRA-2P met<br \/>\n      its primary endpoint, and we look forward to discussing the results with<br \/>\n      the scientific community.&#8221;\n    <\/p>\n<p>\n      Merck will review the data from both TRA2-P and TRACER with the<br \/>\n      investigators and other outside experts to help better understand the<br \/>\n      profile of this investigational medicine in specific patient populations<br \/>\n      and to determine next steps, including potential regulatory filings.\n    <\/p>\n<p>\n      Vorapaxar has been evaluated in two major clinical outcomes studies:<br \/>\n      TRA-2P TIMI 50 (Clinicaltrials.gov identifier: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00526474%3Fterm%3DTRA2-P%2BTIMI%2B50%26rank%3D1&amp;esheet=50280978&amp;lan=en-US&amp;anchor=NCT00526474&amp;index=1&amp;md5=b73ecc57f61f8c50ff4bc43821ded7ea\"><span class=\"bwuline\">NCT00526474<\/span><\/a><br \/>\n      ) was led by the Thrombolysis in Myocardial Infarction (TIMI) Study<br \/>\n      Group of Brigham and Women&#8217;s Hospital. TRA-2P was a secondary prevention<br \/>\n      study in 26,449 patients with a heart attack, an ischemic stroke, or<br \/>\n      documented peripheral vascular disease. TRACER (<b>T<\/b>hrombin <b>R<\/b>eceptor<br \/>\n      <b>A<\/b>ntagonist for <b>C<\/b>linical <b>E<\/b>vent <b>R<\/b>eduction in<br \/>\n      Acute Coronary Syndrome), (Clinicaltrials.gov identifier: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00527943&amp;esheet=50280978&amp;lan=en-US&amp;anchor=NCT00527943&amp;index=2&amp;md5=e6e0e1c76112b1f29dbcd44affb5df62\"><span class=\"bwuline\">NCT00527943<\/span><\/a>)<br \/>\n      was an acute care, hospital-based study of approximately 12,944 patients<br \/>\n      with non-ST-segment-elevation acute coronary syndrome. The study was led<br \/>\n      by the Duke Clinical Research Institute, and results were presented in<br \/>\n      2011 at the American Heart Association Scientific Sessions and published<br \/>\n      in the January 5, 2012 issue of <i>The<\/i> <i>New England Journal of<br \/>\n      Medicine<\/i> (Vol. 366, No. 1). The news release can be found at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fnewsroom%2Fnews-release-archive%2Fresearch-and-development%2F2011_1113.html&amp;esheet=50280978&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fnewsroom%2Fnews-release-archive%2Fresearch-and-development%2F2011_1113.html.&amp;index=3&amp;md5=30748c6ae660969e598d0f8830489dfd\"><span class=\"bwuline\">http:\/\/vip2-msd.com\/merckcom-migrated\/newsroom\/news-release-archive\/research-and-development\/2011_1113.html<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50280978&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=93cfd8b7f3e8989fd22dec797568db8b\"><span class=\"bwuline\">vip2-msd.com\/merckcom-migrated<\/span><\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50280978&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=5&amp;md5=62dffdbfc5e426cb53ffb584b8879df1\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>Skip        Irvine, 267-305-5397<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar. Merck is developing vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, for the prevention of thrombosis, or clot formation, and the reduction of cardiovascular events. TRA-2P showed that the addition of vorapaxar to standard of care significantly reduced the risk of the protocol-specified primary endpoint of the composite of cardiovascular death (CVD), heart attack (myocardial infarction, or MI), stroke or urgent coronary revascularization compared to standard of care. There was a significant increase in bleeding, including intracranial hemorrhage (ICH), among patients taking vorapaxar in addition to standard of care,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742254","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Company Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar. Merck is developing vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, for the prevention of thrombosis, or clot formation, and the reduction of cardiovascular events. TRA-2P showed that the addition of vorapaxar to standard of care significantly reduced the risk of the protocol-specified primary endpoint of the composite of cardiovascular death (CVD), heart attack (myocardial infarction, or MI), stroke or urgent coronary revascularization compared to standard of care. There was a significant increase in bleeding, including intracranial hemorrhage (ICH), among patients taking vorapaxar in addition to standard of care,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/\",\"name\":\"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-02-07T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar - Merck.com","og_description":"Company Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar. Merck is developing vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, for the prevention of thrombosis, or clot formation, and the reduction of cardiovascular events. TRA-2P showed that the addition of vorapaxar to standard of care significantly reduced the risk of the protocol-specified primary endpoint of the composite of cardiovascular death (CVD), heart attack (myocardial infarction, or MI), stroke or urgent coronary revascularization compared to standard of care. There was a significant increase in bleeding, including intracranial hemorrhage (ICH), among patients taking vorapaxar in addition to standard of care,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:26+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/","name":"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-02-07T08:30:00+00:00","dateModified":"2023-03-22T04:04:26+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006709r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f6ab79b9-f1d2-4766-943f-552b62abcecd","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Top-Line-Results-of-TRA-2P-Study-of-Vorapaxar-2012.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742254\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742254"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}